DHR vs KNSA: fair value comparison
Danaher Corporation and Kiniksa Pharmaceuticals International, plc · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, DHR currently sits closer to the top of our ranking by discount to fair value. KNSA carries the stronger quality grade.
| DHR | KNSA | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $219.81 | $78.59 |
| 12-month range | $161.91–$242.05 | $37.01–$80.92 |
| Rank by discount to fair value | #55 of 108 Healthcare | #104 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: DHR fair value analysis · KNSA fair value analysis